GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B4979 Octreotide acetateSummary: octapeptide congener of native somatostatin
- A3681 OlmesartanSummary: Angiotensin II receptor antagonist
- A3684 ONO-AE3-2082 CitationSummary: EP4 receptor antagonist,high affinity and selective
- A3686 OrteronelSummary: For castration-resistant prostate cancer, clinical candidate
- A3691 OtenabantSummary: CB1 receptor antagonist
- A3704 PD 123319 ditrifluoroacetateTarget: Angiotensin AT2 ReceptorsSummary: Angiotensin AT2 receptor antagonist
- A3708 Pentostatin1 CitationTarget: Adenosine DeaminasesSummary: Irreversible adenosine deaminase inhibitor
- A3717 PF-5431 CitationTarget: Sphingosine kinases (SphKs)Summary: SphK1 inhibitor,cell-permeate,potent and selective
- A3723 PhloretinTarget: SGLTSummary: A dihydrochalcone found in apple
- A3735 PreladenantTarget: Adenosine A2A ReceptorsSummary: Adenosine A2A receptor antagonist